Cancer Supportive Care Drug Development Pipeline Review, 2017

This report provides an overview of the Cancer Supportive Care pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for cancer anorexia-cachexia syndrome, bone metastasis and cancer pain, and features dormant and discontinued projects.

Anorexia is defined as the loss of the desire to eat. Progressive wasting is common in many types of cancer and is one of the most important factors leading to early death in cancer patients. Advanced cancer undergo a wasting syndrome associated with cancer anorexia-cachexia and asthenia, which is associated with weakness, fatigue, and a poor quality of life. Bone metastasis occurs when cancer cells spread from their original site to a bone. Signs and symptoms of bone metastasis include bone pain, broken bones, urinary incontinence, bowel incontinence and weakness in the legs. Cancer pain can be defined as a complex sensation that reflects both damage to the body and the body’s response to the damage. Pain may arise due to tumor compressing or infiltrating tissue, from treatments and diagnostic procedures, or from skin, nerve and other changes caused by either the body’s immune response or hormones released by the tumor.

The size of these pipelines ranges 24 products in cancer anorexia-cachexia syndrome to 52 in cancer pain. The majority of products in cancer anorexia-cachexia syndrome target the growth hormone secretagogue receptor type 1, although there are a range of other molecular targets in development. Within bone metastasis, the most common molecular targets are the tumor necrosis factor ligand superfamily member 11, and the hepatocyte growth factor receptor, along with a range of others. Finally, within cancer pain, neurotransmitters such as the mu type opioid receptor, and a range of ion channels, are the most common type of target, reflecting the pain treatment landscape in general.

Scope

– Which companies are the most active within each pipeline?

– Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?

– To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

– What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each

- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these

- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Contents

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 5

1.2 List of Figures 7

2 Introduction 8

2.1 Cancer Supportive Care Report Coverage 8

2.2 Cancer Anorexia-Cachexia Syndrome – Overview 8

2.3 Bone Metastasis – Overview 8

2.4 Cancer Pain – Overview 8

3 Therapeutics Development 9

3.1 Cancer Anorexia-Cachexia Syndrome 9

3.2 Bone Metastasis 15

3.3 Cancer Pain 21

4 Therapeutics Assessment 27

4.1 Cancer Anorexia-Cachexia Syndrome 27

4.2 Bone Metastasis 34

4.3 Cancer Pain 41

5 Companies Involved in Therapeutics Development 49

5.1 Cancer Anorexia-Cachexia Syndrome 49

5.2 Bone Metastasis 54

5.3 Cancer Pain 63

6 Dormant Projects 80

6.1 Cancer Anorexia-Cachexia Syndrome 80

6.2 Bone Metastasis 82

6.3 Cancer Pain 84

7 Discontinued Products 87

7.1 Cancer Anorexia-Cachexia Syndrome 87

7.2 Bone Metastasis 87

7.3 Cancer Pain 88

8 Product Development Milestones 89

8.1 Cancer Anorexia-Cachexia Syndrome 89

8.2 Bone Metastasis 105

8.3 Cancer Pain 118

9 Appendix 127

9.1 Methodology 127

9.2 Coverage 127

9.3 Secondary Research 127

9.4 Primary Research 127

9.5 Expert Panel Validation 127

9.6 Contact Us 128

9.7 Disclaimer 128

List of Tables

1.1 List of Tables

Table 1: Number of Products under Development for Cancer Anorexia-Cachexia Syndrome 9

Table 2: Number of Products under Development by Companies, Cancer Anorexia-Cachexia Syndrome 11

Table 3: Number of Products under Development by Universities/Institutes, Cancer Anorexia-Cachexia Syndrome 12

Table 4: Products under Development by Companies, Cancer Anorexia-Cachexia Syndrome 13

Table 5: Products under Development by Universities/Institutes, Cancer Anorexia-Cachexia Syndrome 14

Table 6: Number of Products under Development for Bone Metastasis 15

Table 7: Number of Products under Development by Companies, Bone Metastasis 17

Table 8: Number of Products under Development by Universities/Institutes, Bone Metastasis 18

Table 9: Products under Development by Companies, Bone Metastasis 19

Table 10: Products under Development by Universities/Institutes, Bone Metastasis 20

Table 11: Number of Products under Development for Cancer Pain 21

Table 12: Number of Products under Development by Companies, Cancer Pain 22

Table 13: Number of Products under Development by Universities/Institutes, Cancer Pain 24

Table 14: Products under Development by Companies, Cancer Pain 24

Table 15: Products under Development by Universities/Institutes, Cancer Pain 26

Table 16: Number of Products by Stage and Target, Cancer Anorexia-Cachexia Syndrome 28

Table 17: Number of Products by Stage and Mechanism of Action, Cancer Anorexia-Cachexia Syndrome 30

Table 18: Number of Products by Stage and Route of Administration, Cancer Anorexia-Cachexia Syndrome 32

Table 19: Number of Products by Stage and Molecule Type, Cancer Anorexia-Cachexia Syndrome 33

Table 20: Number of Products by Stage and Target, Bone Metastasis 35

Table 21: Number of Products by Stage and Mechanism of Action, Bone Metastasis 37

Table 22: Number of Products by Stage and Route of Administration, Bone Metastasis 39

Table 23: Number of Products by Stage and Molecule Type, Bone Metastasis 40

Table 24: Number of Products by Stage and Target, Cancer Pain 42

Table 25: Number of Products by Stage and Mechanism of Action, Cancer Pain 44

Table 26: Number of Products by Stage and Route of Administration, Cancer Pain 47

Table 27: Number of Products by Stage and Molecule Type, Cancer Pain 48

Table 28: Cancer Anorexia-Cachexia Syndrome – Pipeline by Abreos Biosciences Inc 49

Table 29: Cancer Anorexia-Cachexia Syndrome – Pipeline by Acacia Pharma Ltd 49

Table 30: Cancer Anorexia-Cachexia Syndrome – Pipeline by Aeterna Zentaris Inc 50

Table 31: Cancer Anorexia-Cachexia Syndrome – Pipeline by Incyte Corp 50

Table 32: Cancer Anorexia-Cachexia Syndrome – Pipeline by Lakewood-Amedex Inc 51

Table 33: Cancer Anorexia-Cachexia Syndrome – Pipeline by Novartis AG 51

Table 34: Cancer Anorexia-Cachexia Syndrome – Pipeline by Paradigm Biopharmaceuticals Ltd 52

Table 35: Cancer Anorexia-Cachexia Syndrome – Pipeline by RaQualia Pharma Inc 52

Table 36: Cancer Anorexia-Cachexia Syndrome – Pipeline by Viking Therapeutics Inc 53

Table 37: Cancer Anorexia-Cachexia Syndrome – Pipeline by Zeria Pharmaceutical Co Ltd 53

Table 38: Bone Metastasis – Pipeline by Ablynx NV 54

Table 39: Bone Metastasis – Pipeline by Amgen Inc 54

Table 40: Bone Metastasis – Pipeline by Amura Holdings Ltd 55

Table 41: Bone Metastasis – Pipeline by BiologicsMD Inc 55

Table 42: Bone Metastasis – Pipeline by ChemoCentryx Inc 56

Table 43: Bone Metastasis – Pipeline by CSPC Pharmaceutical Group Limited 56

Table 44: Bone Metastasis – Pipeline by Deciphera Pharmaceuticals LLC 57

Table 45: Bone Metastasis – Pipeline by Eli Lilly and Co 57

Table 46: Bone Metastasis – Pipeline by Lupin Ltd 58

Table 47: Bone Metastasis – Pipeline by Mirati Therapeutics Inc 58

Table 48: Bone Metastasis – Pipeline by Oncobiologics Inc 59

Table 49: Bone Metastasis – Pipeline by Oncodrone BV 59

Table 50: Bone Metastasis – Pipeline by OPKO Health Inc 60

Table 51: Bone Metastasis – Pipeline by R Pharm 60

Table 52: Bone Metastasis – Pipeline by Redx Pharma Plc 61

Table 53: Bone Metastasis – Pipeline by Serene LLC 61

Table 54: Bone Metastasis – Pipeline by Taiho Pharmaceutical Co Ltd 62

Table 55: Bone Metastasis – Pipeline by Terpenoid Therapeutics Inc 62

Table 56: Cancer Pain – Pipeline by Alexza Pharmaceuticals Inc 63

Table 57: Cancer Pain – Pipeline by AngioChem Inc 63

Table 58: Cancer Pain – Pipeline by Aoxing Pharmaceutical Company Inc 64

Table 59: Cancer Pain – Pipeline by Aphios Corp 64

Table 60: Cancer Pain – Pipeline by AstraZeneca Plc 65

Table 61: Cancer Pain – Pipeline by ChironWells GmbH 65

Table 62: Cancer Pain – Pipeline by Colby Pharmaceutical Co 66

Table 63: Cancer Pain – Pipeline by ConSynance Therapeutics Inc 66

Table 64: Cancer Pain – Pipeline by Daewoong Pharmaceutical Co Ltd 67

Table 65: Cancer Pain – Pipeline by Daiichi Sankyo Co Ltd 67

Table 66: Cancer Pain – Pipeline by Dompe Farmaceutici SpA 68

Table 67: Cancer Pain – Pipeline by Fujimoto Pharmaceutical Corp 68

Table 68: Cancer Pain – Pipeline by Grunenthal GmbH 69

Table 69: Cancer Pain – Pipeline by Hisamitsu Pharmaceutical Co Inc 69

Table 70: Cancer Pain – Pipeline by Immupharma Plc 70

Table 71: Cancer Pain – Pipeline by Insys Therapeutics Inc 70

Table 72: Cancer Pain – Pipeline by IntelGenx Corp 71

Table 73: Cancer Pain – Pipeline by iX Biopharma Ltd 71

Table 74: Cancer Pain – Pipeline by Klaria Pharma Holding AB 72

Table 75: Cancer Pain – Pipeline by Komipharm International Co Ltd 72

Table 76: Cancer Pain – Pipeline by KPI Therapeutics Inc 73

Table 77: Cancer Pain – Pipeline by Medlab Clinical Ltd 73

Table 78: Cancer Pain – Pipeline by Nanomerics Ltd 74

Table 79: Cancer Pain – Pipeline by Neurocentrx Pharma Ltd 74

Table 80: Cancer Pain – Pipeline by Nippon Kayaku Co Ltd 75

Table 81: Cancer Pain – Pipeline by Orion Corporation 75

Table 82: Cancer Pain – Pipeline by Pain Therapeutics Inc 76

Table 83: Cancer Pain – Pipeline by Pfizer Inc 76

Table 84: Cancer Pain – Pipeline by Pharmaleads SA 77

Table 85: Cancer Pain – Pipeline by Recordati SpA 77

Table 86: Cancer Pain – Pipeline by Ribomic Inc 78

Table 87: Cancer Pain – Pipeline by Trillium Therapeutics Inc 78

Table 88: Cancer Pain – Pipeline by Virobay Inc 79

Table 89: Cancer Pain – Pipeline by WEX Pharmaceuticals Inc 79

Table 90: Cancer Anorexia-Cachexia Syndrome – Dormant Projects 80

Table 91: Bone Metastasis – Dormant Projects 82

Table 92: Cancer Pain – Dormant Projects 84

Table 93: Cancer Anorexia-Cachexia Syndrome – Discontinued Products 87

Table 94: Bone Metastasis – Discontinued Products 87

Table 95: Cancer Pain – Discontinued Products 88

List of Figures

1.2 List of Figures

Figure 1: Number of Products under Development for Cancer Anorexia-Cachexia Syndrome 9

Figure 2: Number of Products under Development by Companies, Cancer Anorexia-Cachexia Syndrome 10

Figure 3: Number of Products under Development by Universities/Institutes, Cancer Anorexia-Cachexia Syndrome 12

Figure 4: Number of Products under Development for Bone Metastasis 15

Figure 5: Number of Products under Development by Companies, Bone Metastasis 16

Figure 6: Number of Products under Development by Universities/Institutes, Bone Metastasis 18

Figure 7: Number of Products under Development for Cancer Pain 21

Figure 8: Number of Products under Development by Companies, Cancer Pain 22

Figure 9: Number of Products by Top 10 Targets, Cancer Anorexia-Cachexia Syndrome 27

Figure 10: Number of Products by Stage and Top 10 Targets, Cancer Anorexia-Cachexia Syndrome 27

Figure 11: Number of Products by Top 10 Mechanism of Actions, Cancer Anorexia-Cachexia Syndrome 29

Figure 12: Number of Products by Stage and Top 10 Mechanism of Actions, Cancer Anorexia-Cachexia Syndrome 29

Figure 13: Number of Products by Routes of Administration, Cancer Anorexia-Cachexia Syndrome 31

Figure 14: Number of Products by Stage and Routes of Administration, Cancer Anorexia-Cachexia Syndrome 31

Figure 15: Number of Products by Molecule Types, Cancer Anorexia-Cachexia Syndrome 32

Figure 16: Number of Products by Stage and Molecule Types, Cancer Anorexia-Cachexia Syndrome 33

Figure 17: Number of Products by Top 10 Targets, Bone Metastasis 34

Figure 18: Number of Products by Stage and Top 10 Targets, Bone Metastasis 34

Figure 19: Number of Products by Top 10 Mechanism of Actions, Bone Metastasis 36

Figure 20: Number of Products by Stage and Top 10 Mechanism of Actions, Bone Metastasis 36

Figure 21: Number of Products by Routes of Administration, Bone Metastasis 38

Figure 22: Number of Products by Stage and Routes of Administration, Bone Metastasis 38

Figure 23: Number of Products by Molecule Types, Bone Metastasis 39

Figure 24: Number of Products by Stage and Molecule Types, Bone Metastasis 40

Figure 25: Number of Products by Top 10 Targets, Cancer Pain 41

Figure 26: Number of Products by Stage and Top 10 Targets, Cancer Pain 41

Figure 27: Number of Products by Top 10 Mechanism of Actions, Cancer Pain 43

Figure 28: Number of Products by Stage and Top 10 Mechanism of Actions, Cancer Pain 44

Figure 29: Number of Products by Routes of Administration, Cancer Pain 46

Figure 30: Number of Products by Stage and Routes of Administration, Cancer Pain 46

Figure 31: Number of Products by Molecule Types, Cancer Pain 47

Figure 32: Number of Products by Stage and Molecule Types, Cancer Pain 48

    Pricing

Quick Buy
Add to basket Request sample pages

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports